Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer’s disease
Publish place: Iranian Journal of Basic Medical Sciences، Vol: 20، Issue: 5
Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 167
This Paper With 7 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJBMS-20-5_004
تاریخ نمایه سازی: 28 مهر 1400
Abstract:
Objective(s): Increasing evidence suggests that Alzheimer’s disease (AD) is associated with diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD. However, the underlying therapeutic potential of it has not been fully elucidated. Materials and Methods: Rats were divided into four groups: control group, sham operated group, Streptozotocin (STZ) group, rosiglitazone (RGZ) group. Particularly, the STZ-induced rat model was established by intracerebroventricular injection (۳ mg/kg) on the first and third day. The water maze behavioral test was performed to evaluate spatial reference learning and memory of the rats. Aβ۱-۴۰ and Aβ۱-۴۲ levels were measured by ELISA method. To determine APP-derived fragment, BACE۱ and Aβ degrading enzymes levels, such as NEP and IDE, as well as Aβ transportation protein level, such as LRP۱, RAGE, Abca۱ and APOE , which were analyzed by Western blot. Immunohistochemistry was used to observe the change of Aβ۱-۴۰ and Aβ۱-۴۲ in hippocampus. Results: Chronic treatment with RGZ could reduce the Aβ level and improved spatial memory performance in STZ-induced rat model. However, RGZ modified the expression of specific transport proteins monitoring Aβ clearance, such as ATP-binding cassette transporter ۱ (ABCA۱), lipoprotein receptor-related protein ۱ (LRP۱), and the advanced glycation end product-specific receptor (RAGE) rather than change levels of Aβ degrading enzymes, such as IDE and NEP, nor affect APP processing. Conclusion: As a potential therapeutic strategy, rosiglitazone might exert anti-AD effect not by alteration of APP processing pathway and Aβ degradation directly, but through promotion of Aβ clearance indeed.
Keywords:
Alzheimer’s disease , Amyloid precursor protein processing , β-amyloid peptide clearance , Peroxisome proliferator activated receptor γ
Authors
Li Wang
Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin ۱۵۰۰۸۱, China
Wei Liu
Department of Neurology, Peking University Third Hospital, Beijing ۱۰۰۰۸۰, China
Ying Fan
Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin ۱۵۰۰۸۱, China
Tingting Liu
Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin ۱۵۰۰۸۱, China
Chunjiang Yu
Department of Neurology, The Second Affiliated Hospital of the Harbin Medical University, Harbin ۱۵۰۰۸۱, China
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :